Dr. Mager is Professor and Chair of Pharmaceutical Sciences at the University at Buffalo, State
University of New York. He is also President and CEO of Enhanced Pharmacodynamics, LLC. He is a Fellow and Past President of both ACCP and ISoP. He is also a Fellow of AAPS, AAAS, and FIP, of which he serves as Acting Vice President via the Board of Pharmaceutical Sciences. He is also a member of the Scientific Advisory Board to Simcyp. His current research efforts seek to combine network-based analysis with empirical and systems models to explore combinatorial anti-cancer drug regimens, heterogeneity in cancer responses, and chemotherapy-induced adverse drug reactions. He served as a Co-Editor of Systems Pharmacology and Pharmacodynamics and has contributed to 170+ peer-reviewed publications.
Dr. Mager is Professor and Chair of Pharmaceutical Sciences at the University at Buffalo, State
University of New York. He is also President and CEO of Enhanced Pharmacodynamics, LLC. He is a Fellow and Past President of both ACCP and ISoP. He is also a Fellow of AAPS, AAAS, and FIP, of which he serves as Acting Vice President via the Board of Pharmaceutical Sciences. He is also a member of the Scientific Advisory Board to Simcyp. His current research efforts seek to combine network-based analysis with empirical and systems models to explore combinatorial anti-cancer drug regimens, heterogeneity in cancer responses, and chemotherapy-induced adverse drug reactions. He served as a Co-Editor of Systems Pharmacology and Pharmacodynamics and has contributed to 170+ peer-reviewed publications.